Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Verzenio
|
| gptkbp:activities |
estrogen receptor antagonist
|
| gptkbp:approves |
gptkb:1977
gptkb:FDA |
| gptkbp:brand |
Nolvadex
Tamofen Tamoxtat |
| gptkbp:class |
selective estrogen receptor modulator (SERM)
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:contraindication |
liver disease
pregnancy history of blood clots lactation |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:discovered_by |
1960s
D. J. C. H. Houghton |
| gptkbp:dosage_form |
20 mg daily
40 mg daily 10 mg daily |
| https://www.w3.org/2000/01/rdf-schema#label |
tamoxifen
|
| gptkbp:ingredients |
C26 H29 NO
|
| gptkbp:interacts_with |
anticoagulants
CY P2 D6 inhibitors SSR Is |
| gptkbp:is_atype_of |
L02 B A01
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
infertility treatment ductal carcinoma in situ |
| gptkbp:lifespan |
5 to 7 days
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
1970s
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
reproductive health
endocrinology oncology pharmacology |
| gptkbp:side_effect |
gptkb:historical_event
anxiety fatigue nausea thromboembolic events weight gain headaches mood swings blood clots skin rash hair loss hot flashes vaginal dryness visual disturbances endometrial cancer risk vaginal discharge |
| gptkbp:type_of |
10540-29-1
|